News

The IXORA-R trial is the first completed head-to-head (H2H) trial between an IL-17A inhibitor and an IL-23/p19 inhibitor using the Psoriasis Area Severity Index (PASI) 100 score as

The financing was co-led by RTW Investments and Perceptive Advisors (Perceptive Xontogeny Venture Fund and Perceptive Life Sciences Fund), and joined by additional new investors, including Osage University

The approval has been granted for the use of ibrutinib in combination with obinutuzumab in adult patients with previously untreated chronic lymphocytic leukaemia (CLL), as well as the

CARES10 is a United States/Canada-based open-label, prospective, multi-center phase 3 clinical study to assess efficacy, safety and pharmacokinetics of a 10 percent intravenous immunoglobulin in the treatment of

BridgeBio currently owns, through its wholly-owned subsidiary, BridgeBio Pharma LLC, approximately 66.6% of the outstanding shares of the Company’s common stock. According to the terms of the Proposal,

In this regard, Boehringer Ingelheim and MD Anderson plan to set up a joint Virtual Research and Development Center to facilitate effective data sharing and analysis among themselves.

As per terms of the deal, the former Cavion shareholders have secured an upfront payment of $52.5m (£43.5m). They are also eligible to receive additional payments of around

Ascletis’ Clinical Development Shanghai Center is at the heart of Shanghai, located at Jing’an Kerry Centre near Nanjing West Road. The opening ceremony was held on Aug 11,

Aquinox Pharmaceuticals, Inc. will be renamed Neoleukin Therapeutics, Inc. and will trade under the new ticker symbol “NLTX” beginning on Monday, August 12, 2019, on the Nasdaq Global